Literature DB >> 19463449

Predictors and outcomes of ad hoc versus non-ad hoc percutaneous coronary interventions.

Edward L Hannan1, Zaza Samadashvili, Gary Walford, David R Holmes, Alice Jacobs, Samin Sharma, Stanley Katz, Spencer B King.   

Abstract

OBJECTIVES: Our aim was to compare longer-term outcomes for ad hoc percutaneous coronary intervention (PCI) and non-ad hoc PCI.
BACKGROUND: Ad hoc PCIs, whereby PCI is performed immediately after cardiac catheterization, has become the most common way of performing PCI. However, no studies have compared longer-term outcomes for ad hoc and non-ad hoc PCIs.
METHODS: A total of 46,565 New York State patients who underwent PCI in nonfederal New York State hospitals between January 1, 2003 and June 30, 2005 were followed through December 31, 2005, and in-hospital and longer-term outcomes were compared for ad hoc and non-ad hoc PCI patients after adjusting for differences in pre-procedural risk factors.
RESULTS: There was no difference in risk-adjusted in-hospital mortality (adjusted ad hoc/non-ad hoc odds ratio: 0.82, 95% confidence interval [CI]: 0.55 to 1.22). Ad hoc PCI patients had significantly lower 36-month mortality (adjusted hazard ratio [HR]: 0.76, 95% CI: 0.69 to 0.85, p < 0.0001). Ad hoc PCI patients had significantly higher 36-month subsequent revascularization (adjusted HR: 1.11, 95% CI: 1.01 to 1.21, p = 0.03), but after excluding subsequent PCIs that occurred within 30 days of the index PCI in another vessel, the difference was no longer significant (adjusted HR: 1.03, 95% CI: 0.95 to 1.12, p = 0.43).
CONCLUSIONS: On average, lower-risk patients undergo ad hoc PCI, and after risk-adjustment for differences in patient mix, ad hoc PCI patients have lower 3-year mortality rates.

Entities:  

Mesh:

Year:  2009        PMID: 19463449     DOI: 10.1016/j.jcin.2009.01.006

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  7 in total

1.  Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

Authors:  Devraj Sukul; Milan Seth; Simon R Dixon; Akshay Khandelwal; Thomas A LaLonde; Hitinder S Gurm
Journal:  J Invasive Cardiol       Date:  2017-04-15       Impact factor: 2.022

2.  Appropriateness of percutaneous coronary intervention.

Authors:  Paul S Chan; Manesh R Patel; Lloyd W Klein; Ronald J Krone; Gregory J Dehmer; Kevin Kennedy; Brahmajee K Nallamothu; W Douglas Weaver; Frederick A Masoudi; John S Rumsfeld; Ralph G Brindis; John A Spertus
Journal:  JAMA       Date:  2011-07-06       Impact factor: 56.272

3.  Long-term outcome following remote ischemic postconditioning during percutaneous coronary interventions-the RIP-PCI trial long-term follow-up.

Authors:  Shahar Lavi; Nour Abu-Romeh; Sabrina Wall; Mistre Alemayehu; Ronit Lavi
Journal:  Clin Cardiol       Date:  2017-01-11       Impact factor: 2.882

4.  The effects of data sources, cohort selection, and outcome definition on a predictive model of risk of thirty-day hospital readmissions.

Authors:  Colin Walsh; George Hripcsak
Journal:  J Biomed Inform       Date:  2014-08-23       Impact factor: 6.317

Review 5.  Heart Team-the Indian perspective.

Authors:  Kunal Sarkar
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2018-11-16

6.  Shared decision making in patients with stable coronary artery disease: PCI choice.

Authors:  Megan Coylewright; Kathy Shepel; Annie Leblanc; Laurie Pencille; Erik Hess; Nilay Shah; Victor M Montori; Henry H Ting
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  Vessel segmentation for X-ray coronary angiography using ensemble methods with deep learning and filter-based features.

Authors:  Zijun Gao; Lu Wang; Reza Soroushmehr; Alexander Wood; Jonathan Gryak; Brahmajee Nallamothu; Kayvan Najarian
Journal:  BMC Med Imaging       Date:  2022-01-19       Impact factor: 1.930

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.